Overall, similar proportions of patients in the dapagliflozin andglipizide groups experienced at least one AE (87.7 vs 87.0%) or serious AE [18.5 vs 19.9% (Table 2)]. The higher discontinuation rate in the dapagliflozin group compared with the glipizide group (as a result of an AE, 13.3 vs 11.3%) was attributed to more discontinuations because of decreased renal creatinine clearance compared with the glipizide group [16 vs 10 patients
(Table 3)].